SynAct Pharma AB (FRA:8F8)

SynAct Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-106.28	-82.4	-215.81	-99.21	-69.3	-26.55
Depreciation & Amortization	0.62	0.62	75.34	1.02	0.09	-
Loss (Gain) From Sale of Assets	-0.05	-0.05	-0.04	-0.01	-	-
Stock-Based Compensation	10.07	10.07	7.88	-	-	-
Other Operating Activities	-12.6	0.85	2.09	1	-2.88	-3.92
Change in Accounts Receivable	-19.63	-19.63	19.87	-19.31	-1.21	-0.53
Change in Accounts Payable	7.33	7.33	5.11	0.18	1.44	-0.33
Change in Other Net Operating Assets	29.4	-5.97	5.39	-1.22	6.87	-1.91
Operating Cash Flow	-91.14	-89.2	-100.18	-117.56	-65	-33.24
Investment in Securities	-	-	0.37	0.03	-0.01	-0.09
Investing Cash Flow	-	-	0.37	0.03	-0.01	-0.09
Long-Term Debt Repaid	-	-0.6	-0.73	-0.98	-0.08	-
Net Debt Issued (Repaid)	-0.6	-0.6	-0.73	-0.98	-0.08	-
Issuance of Common Stock	131.15	94.14	59.46	228.95	80	49.76
Other Financing Activities	0.25	-6.14	-4.75	-27.25	-5.6	-5.04
Financing Cash Flow	130.8	87.41	53.98	200.71	74.32	44.72
Foreign Exchange Rate Adjustments	-0.21	0.61	-0.03	1.06	0.13	-0.35
Miscellaneous Cash Flow Adjustments	0	-0	-	0	-0	0
Net Cash Flow	39.45	-1.19	-45.85	84.25	9.45	11.04
Cash Interest Paid	0.98	0.98	0.12	0.12	0.11	2.36
Cash Income Tax Paid	-	-8.43	-8.47	-7.86	-4.63	-3.17
Levered Free Cash Flow	-46.28	-62.5	18.74	-86.61	-43.28	-12.14
Unlevered Free Cash Flow	-45.18	-61.99	19.24	-86.43	-43.21	-12.11
Change in Working Capital	17.1	-18.28	30.37	-20.35	7.1	-2.77

Source: S&P Global Market Intelligence. Standard template. Financial Sources.